Renalytix plc - Sponsored ADR RNLXY
4.00
(0.17)
(4.08%)
as of 24 Sep
- Market cap
- $17.2M
- P/E
- 0.0×
Follow RNLXY
Growth Flags
show if company had growth for consecutive years
| Jun '25 | Dec '24 | Sep '24 | Jun '24 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | 116.86 | 147.79 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (71.99) | (45.23) | |
P/B ratio |
— | — | 0.00 | 0.00 | |
Price to Tangible BV |
— | — | 0.00 | 0.00 | |
EV/Sales |
— | — | 118.22 | 147.31 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (11.58) | (11.37) | |
EV/FCF |
— | — | (11.40) | (11.23) | |
Quick Ratio |
— | 2.22 | 0.15 | 0.52 | |
Current Ratio |
— | 2.43 | 0.24 | 0.58 | |
Net Debt/EBITDA |
— | 0.00 | (0.79) | 0.22 | |
Debt/Assets |
0.00% | 71.72% | 85.52% | 60.56% | |
Debt/Equity |
— | (5.99) | (0.36) | (0.48) | |
Asset Turnover |
0.00 | 0.00 | 0.19 | 0.12 | |
Operating CF/Net income |
— | 0.00 | 0.81 | 0.39 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
— | — | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | — | 176.44% | 177.89% | |
Selling, General and Administrative Expense of Revenue |
— | — | 626.63% | 2,587.60% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | 48.66% | (31.99%) | |
Graham Net Nets |
— | — | (0.05) | (0.03) | |
Graham Number |
— | — | 46.41 | 44.30 | |
Earnings Yield |
— | — | (13.69%) | (13.39%) | |
Free Cash Flow Yield |
— | — | (8.87%) | (8.88%) | |
Revenue per Share |
— | — | 0.25 | 0.28 | |
Operating CF per Share |
— | 0.00 | (1.81) | (3.47) | |
Capex per Share |
— | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
— | 0.00 | (1.81) | (3.47) | |
Cash per Share |
— | 0.00 | 0.43 | 2.49 | |
Shareholders Equity per Share |
— | 0.00 | (5.35) | (4.15) | |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | |
Book value per Share |
— | 0.00 | (5.35) | (4.15) | |
Free Cash Flow |
— | (6.50) | (3.84) | (7.52) | |
Working Capital |
— | 6.59 | (9.13) | (5.00) | |
Capital Expenditures |
— | — | — | 0.00 | |
Net Current Asset Value |
— | (1.62) | (13.23) | (9.30) | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Net Profit Margin |
— | — | (905.75%) | (3,202.35%) | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 0.94 | 0.96 | 0.74 | |
Average Payables |
— | 3.71 | 4.48 | 5.27 | |
Average Inventory |
— | 0.42 | — | 0.20 | |
Average Assets |
4.38 | 11.36 | 12.17 | 18.86 | |
Average Common Equity |
— | (4.66) | (6.40) | (1.02) |
Columns are period end dates